Novanta (NOVT) AI Stock Analysis

• Market Cap: $4.93B
• Dividend Yield: N/A
• Average Volume (3M): 406.42K
• Price to Earnings (P/E): 94.7
• Beta (1Y): 1.68
• Revenue Growth: 4.07%
• EPS Growth: -12.34%
• Country: US
• Employees: 3,000
• Sector: Technology
• Sector Strength: 88
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 0.91
• Shares Outstanding: 35,683,770
• 10 Day Avg. Volume: 405,257
• 30 Day Avg. Volume: 406,418
• PEG Ratio: -4.64
• Price to Book (P/B): 3.31
• Price to Sales (P/S): 4.44
• P/FCF Ratio: 89.90
• Enterprise Value/Market Cap: 1.01
• Enterprise Value/Revenue: 5.08
• Enterprise Value/Gross Profit: 11.44
• Enterprise Value/Ebitda: 29.85
• 1Y Price Target: $150.00
• Price Target Upside: 8.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 3.61
• Revenue Forecast (FY): $1.04B

• Rating: 62 Neutral
• Price Target: $151.00 ▲(9.28% Upside)
• Action: Reiterated Date: 02/24/26
• Date: Action: Reiterated 02/24/26

The score is anchored by solid financial foundations (notably deleveraging) and constructive technical momentum, plus a bullish FY2026 outlook for margin and cash flow recovery from management. These positives are offset by the weak 2025 cash flow performance and a very expensive valuation (high P/E), which raises downside sensitivity if execution on the cash and margin rebound falls short.

Positive Factors

Design-in driven revenue model

Novanta's business is design-in driven: once a component is qualified into an OEM platform, it generates repeat production orders over program life. This creates durable revenue visibility, higher customer switching costs in regulated medical end markets, and structural defensibility versus commoditized suppliers.

Strengthened balance sheet / net cash

A net cash position and materially reduced revolver use markedly lower financial risk and provide long-term flexibility. This balance sheet strength supports acquisition optionality, R&D investment, and the ability to absorb cyclical shocks without forcing dilutive financing or deep cost cuts.

New product momentum & design wins

Rapid new product adoption indicates ongoing product innovation and successful design-ins, which drive higher-value, stickier revenue streams. Over 2–6 months this supports share gains, a healthier product mix, and the potential for sustainably higher margins as newer solutions scale within OEM platforms.

Negative Factors

Weakened operating and free cash flow

The sharp year-over-year cash flow decline materially reduces financial flexibility and raises execution risk. Persistent volatility in cash conversion constrains reinvestment, debt repayment or M&A without drawing on liquidity, and makes delivery of management's recovery guidance more operationally sensitive.

Operating margin compression

A large, rapid margin decline signals structural pressure from mix, dual-running costs or pricing/headwinds. If sustained, lower operating margins erode free cash flow and return on invested capital, making it harder to fund growth and justify expansion without material efficiency gains or pricing power restoration.

Working-capital and inventory build from regional transfers

Higher inventories and dual-running costs create a persistent cash drag and raise execution risk tied to the timing of transfer completion. If transfers or customer ramp schedules slip, working-capital pressure can recur, delaying cash-flow normalization and constraining margin recovery over the medium term.

Novanta Business Overview & Revenue Model

Company Description

Novanta Inc., together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide. The company's Photonics segment offers photonics-based solutions, including laser scanning and beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products serving photonics-based applications for industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. It's Vision segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless technologies, video recorders, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. In addition, its Precision Motion segment offers optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles. The company sells its products through its direct sales force, resellers, distributors, and system integrators under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was founded in 1968 and is headquartered in Bedford, Massachusetts.

How the Company Makes Money

Novanta generates revenue through the sale of its precision components and systems, focusing on high-margin products that cater to specialized markets. The company's key revenue streams include sales of laser and imaging systems, motion control solutions, and optical products. Additionally, Novanta benefits from recurring revenue through service contracts and maintenance agreements for their systems. Strategic partnerships with leading companies in the medical and industrial sectors enhance its market position, while ongoing investments in research and development allow for innovation and the introduction of new technologies, further contributing to its earnings.

Novanta Financial Statement Overview

Summary

Strong multi-year revenue growth and a materially improved leverage profile (net cash position supported by lower debt-to-equity), but 2025 showed meaningful pressure in profitability (EBITDA margin compression) and a sharp deterioration in operating/free cash flow, which is a key near-term risk.

Income Statement

Revenue has grown steadily over the last several years (from $591M in 2020 to $981M in 2025), with a very strong 2025 growth rate shown in the data. Profitability, however, has softened recently: net margin fell to ~5.5% in 2025 from ~6.8% in 2024, and EBITDA margin compressed to ~9.6% in 2025 from ~18.9% in 2024. Gross margin remains relatively stable around the mid-40% range, but the step-down in operating-level profitability is a key concern.

Balance Sheet

Leverage has improved meaningfully, with debt-to-equity declining from ~0.95 (2021) to ~0.63 (2024) and down to ~0.23 in 2025, indicating a stronger capital structure and lower financial risk. Equity also expanded sharply in 2025, supporting balance sheet flexibility. The main watch item is the year-to-year volatility in the capital base and debt levels (which can reflect acquisition activity, financing moves, or accounting impacts), but overall balance sheet strength looks improved.

Cash Flow

Cash generation weakened materially in 2025: operating cash flow dropped to ~$64M from ~$159M in 2024, and free cash flow fell to ~$48M from ~$141M (down ~53% year over year). Free cash flow still covered net income reasonably (about 76% in 2025), but the sharp decline in absolute cash flow and the much lower cash conversion versus 2024 are notable risks and reduce financial flexibility.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	980.60M	949.25M	881.66M	860.90M	706.79M
Gross Profit	435.28M	421.55M	399.90M	378.47M	300.33M
EBITDA	153.05M	179.86M	169.92M	160.62M	125.47M
Net Income	53.83M	64.09M	72.88M	74.05M	50.33M
Balance Sheet
Total Assets	1.81B	1.39B	1.23B	1.24B	1.23B
Cash, Cash Equivalents and Short-Term Investments	380.87M	113.99M	105.05M	100.11M	117.39M
Total Debt	341.61M	471.00M	404.56M	489.38M	493.40M
Total Liabilities	492.82M	642.81M	552.60M	663.63M	706.59M
Stockholders Equity	1.31B	745.70M	673.46M	577.59M	521.29M
Cash Flow
Free Cash Flow	48.43M	141.35M	100.11M	71.14M	72.45M
Operating Cash Flow	64.06M	158.51M	120.08M	90.78M	94.63M
Investing Cash Flow	-74.32M	-208.19M	-19.89M	-42.54M	-306.70M
Financing Cash Flow	276.33M	56.94M	-97.85M	-60.15M	204.75M

Novanta Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 138.18
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NOVT, the sentiment is Neutral. The current price of 138.18 is below the 20-day moving average (MA) of 140.50, above the 50-day MA of 133.29, and above the 200-day MA of 121.85, indicating a neutral trend. The MACD of 1.06 indicates Positive momentum. The RSI at 50.27 is Neutral, neither overbought nor oversold. The STOCH value of 39.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NOVT.

Novanta Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ESE	80 Outperform	$7.27B	44.07	9.25%	0.16%	13.13%	24.02%
VICR	77 Outperform	$9.02B	77.55	18.50%	―	11.55%	1745.46%
PLXS	74 Outperform	$5.19B	30.15	12.63%	―	1.82%	56.52%
OSIS	68 Neutral	$4.73B	27.58	18.33%	―	9.37%	15.70%
ST	68 Neutral	$5.15B	155.81	-0.92%	1.43%	-8.07%	63.50%
NOVT	62 Neutral	$4.93B	94.72	5.23%	―	4.07%	-12.34%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%

Novanta Corporate Events

Novanta Appoints New General Counsel Manganiello

Novanta Inc. has appointed Alexander Manganiello as General Counsel and Corporate Secretary, effective December 1, 2025. This strategic appointment brings Manganiello’s extensive 30-year legal experience to the company, potentially strengthening its global legal and regulatory framework, which may enhance Novanta’s industry positioning.

The most recent analyst rating on (NOVT) stock is a Hold with a $115.00 price target. To see the full list of analyst forecasts on Novanta stock, see the NOVT Stock Forecast page.